About Madrigal Pharmaceuticals, Inc.
https://www.madrigalpharma.comMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.
CEO
William J. Sibold
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2016-07-25 | Reverse | 1:35 |
ETFs Holding This Stock
VTS.AX
Weight:0.02%
Shares:561.82K
IWM
Weight:0.34%
Shares:456.83K
XSU.TO
Weight:0.35%
Shares:456.83K
Summary
Showing Top 3 of 169
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
B. Riley Securities
Buy
HC Wainwright & Co.
Buy
Truist Securities
Buy
Canaccord Genuity
Buy
TD Cowen
Buy
UBS
Buy
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:2.14M
Value:$1.08B
RTW INVESTMENTS, LP
Shares:1.99M
Value:$1.01B
PAULSON & CO. INC.
Shares:1.91M
Value:$963.74M
Summary
Showing Top 3 of 404
About Madrigal Pharmaceuticals, Inc.
https://www.madrigalpharma.comMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $287.27M ▲ | $383.12M ▲ | $-114.19M ▼ | -39.75% ▼ | $-5.08 ▼ | $-106.38M ▼ |
| Q2-2025 | $212.8M ▲ | $250.94M ▲ | $-42.28M ▲ | -19.87% ▲ | $-1.9 ▲ | $-38.64M ▲ |
| Q1-2025 | $137.25M ▲ | $212.05M ▲ | $-73.24M ▼ | -53.36% ▲ | $-3.32 ▼ | $-69.56M ▼ |
| Q4-2024 | $103.32M ▲ | $166.87M ▼ | $-59.42M ▲ | -57.51% ▲ | $-2.71 ▲ | $-55.55M ▲ |
| Q3-2024 | $62.17M | $176.33M | $-106.96M | -172.04% | $-4.92 | $-102.99M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.11B ▲ | $1.36B ▲ | $736.73M ▲ | $625.73M ▼ |
| Q2-2025 | $797.02M ▼ | $1.02B ▲ | $319.4M ▲ | $695.98M ▼ |
| Q1-2025 | $843.07M ▼ | $996.63M ▼ | $285.99M ▼ | $710.64M ▼ |
| Q4-2024 | $926.25M ▼ | $1.04B ▼ | $287.86M ▼ | $754.38M ▼ |
| Q3-2024 | $998.63M | $1.07B | $296.11M | $777.15M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-114.19M ▼ | $79.85M ▲ | $-207M ▼ | $236.65M ▲ | $109.5M ▲ | $78.99M ▲ |
| Q2-2025 | $-42.28M ▲ | $-47.05M ▲ | $47.86M ▼ | $1.74M ▼ | $2.55M ▼ | $-47.05M ▲ |
| Q1-2025 | $-73.24M ▼ | $-88.89M ▲ | $163.88M ▲ | $8.64M ▼ | $83.63M ▲ | $-88.89M ▲ |
| Q4-2024 | $-59.42M ▲ | $-104.49M ▼ | $-47.95M ▲ | $19.77M ▲ | $-132.66M ▲ | $-104.68M ▼ |
| Q3-2024 | $-106.96M | $-66.98M | $-202.39M | $7.46M | $-261.91M | $-67.76M |
CEO
William J. Sibold
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2016-07-25 | Reverse | 1:35 |
ETFs Holding This Stock
VTS.AX
Weight:0.02%
Shares:561.82K
IWM
Weight:0.34%
Shares:456.83K
XSU.TO
Weight:0.35%
Shares:456.83K
Summary
Showing Top 3 of 169
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
B. Riley Securities
Buy
HC Wainwright & Co.
Buy
Truist Securities
Buy
Canaccord Genuity
Buy
TD Cowen
Buy
UBS
Buy
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:2.14M
Value:$1.08B
RTW INVESTMENTS, LP
Shares:1.99M
Value:$1.01B
PAULSON & CO. INC.
Shares:1.91M
Value:$963.74M
Summary
Showing Top 3 of 404